MARKET

ENTO

ENTO

Entero Therapeutics
NASDAQ
0.5001
-0.0143
-2.78%
Closed 16:00 02/18 EST
OPEN
0.5145
PREV CLOSE
0.5144
HIGH
0.5300
LOW
0.5001
VOLUME
23.97K
TURNOVER
--
52 WEEK HIGH
9.35
52 WEEK LOW
0.1850
MARKET CAP
2.38M
P/E (TTM)
-0.0690
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENTO last week (0210-0214)?
Weekly Report · 1d ago
Entero Therapeutics appoints interim CEO
Seeking Alpha · 4d ago
Entero Therapeutics names Richard Paolone as interim CEO
TipRanks · 4d ago
Press Release: Entero Therapeutics Appoints Richard Paolone as CEO
Dow Jones · 4d ago
Weekly Report: what happened at ENTO last week (0203-0207)?
Weekly Report · 02/10 09:32
Entero Therapeutics secures $2M revolving loan, appoints three new directors
TipRanks · 02/07 20:40
Entero Therapeutics Secures $2M Loan; Appoints Three New Board Members After Replacing 3 Of 5 Of Its Directors
Benzinga · 02/07 20:23
ENTERO THERAPEUTICS SECURES $2 MILLION REVOLVING LOAN; APPOINTS THREE NEW BOARD MEMBERS
Reuters · 02/07 20:22
More
About ENTO
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

Webull offers Entero Therapeutics Inc stock information, including NASDAQ: ENTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTO stock methods without spending real money on the virtual paper trading platform.